Hi Ben Like many others I suspect , I "benchmark"your posts , to help me understand where IMU are in the wider scheme of their activities , as the real clinical science of the three elements of what they are doing is above my pay grade . So ....on the subject of the Oasis Trial ....as I understand it , 40 patients overall in current trial status ( from last publication ?) , and recruiting more ....but its this Nov 11the 2024 Announcement below that draws my current attention : Specifically : 1st Patient : Colorectal cancer : Early Nov 2024 administered .
Would be pleased to get your opinion ( and any others of course ) , of an update on this TRIAL IN GENERAL , and this first patient progress , would be likely after some 90 days from the first treatment , and perhaps it could be another catalyst that demonstrates some real progress ? I appreciate a trial of 1 is negligible --but , in the wider context of the trials of 40 ( in other chapters of cancer I presume ) , might be very well received , given colorectal cancer is so prevalent ??!! Thanks in advance
Edit 11th Nov Announcement Phase 1 onCARlytics Trial Doses First Patient in Intratumoural (IT) Combination Arm • First patient dosed in the intratumoural (IT) injection combination arm of the OASIS trial • The colorectal cancer patient was dosed at Northwestern University • OASIS combines a CD19-expressing oncolytic virus with a CD19-targeting drug, and is expected to recruit up to 40 patients with advanced solid cancers that have spread • The onCARlytics trial is designed to convert hard-to-treat “targetless” tumours to CD19-expressing solid tumours that can be targeted
IMU Price at posting:
4.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)